2024
Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis
Ghosh H, Patel R, Claus E, Castro L, Wen P, Ligon K, Meredith D, Bi W. Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosis. Neuro-Oncology 2024, 27: 993-1003. PMID: 39584448, PMCID: PMC12083226, DOI: 10.1093/neuonc/noae258.Peer-Reviewed Original ResearchFocal gene amplificationsCDKN2A/B lossFocal amplificationGene amplificationAssociated with worse survivalAssociated with reduced survivalGrade 4 casesGrade 4 patientsLoss of CDKN2A/BMolecular featuresOverall survival predictionIntermediate prognosisTumor gradeWorse survivalIDH1/2-mutantShorter survivalHistological criteriaStratify riskPoor outcomeHistological featuresCDKN2A/BHomozygous lossAcademic medical centerGrade 2Glioma diagnostics
2023
Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency
Stecklein S, Barlow W, Pusztai L, Timms K, Kennedy R, Logan G, Seitz R, Badve S, Gökmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi G, Godwin A, Thompson A, Hayes D, Sharma P. Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency. JCO Precision Oncology 2023, 7: e2300197. PMID: 37972336, PMCID: PMC10681491, DOI: 10.1200/po.23.00197.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerHomologous recombination deficiencyBreast cancerAdjuvant anthracycline-based chemotherapyTherapeutic vulnerabilitiesRecombination deficiencyDistinct therapeutic vulnerabilitiesAnthracycline-based chemotherapyImmune response signaturesDNA-damaging therapiesFavorable prognosisIntermediate prognosisWorse prognosisImmunologic microenvironmentImmune responseChemoresistant tumorsPrognostic classificationHeterogeneous diseasePrognosisHeterogeneous groupDistinct subgroupsTumorsCancerResponse signatureSimultaneous assessment
2019
ALCL by any other name: the many facets of anaplastic large cell lymphoma
Irshaid L, Xu ML. ALCL by any other name: the many facets of anaplastic large cell lymphoma. Pathology 2019, 52: 100-110. PMID: 31706671, DOI: 10.1016/j.pathol.2019.09.007.Peer-Reviewed Original ResearchConceptsAnaplastic large cell lymphomaAnaplastic lymphoma kinaseALK gene translocationALK(-) ALCLLarge cell lymphomaALK gene rearrangementVariable prognosisFavorable prognosisCell lymphomaGene rearrangementsNon-Hodgkin T-cell lymphomaExtent of diseaseLarge lymphoma cellsT-cell lymphomaGene translocationSpecific gene rearrangementsPatient demographicsIntermediate prognosisDismal prognosisImmunohistochemical phenotypeClinical behaviorFavorable outcomeDifferential diagnosisImplant placementSkin lesions
2007
Distinct Prognostic Role of Prostate-Specific Antigen Doubling Time and Velocity at Emergence of Androgen Independence in Patients Treated with Chemotherapy
Daskivich T, Regan M, Oh W. Distinct Prognostic Role of Prostate-Specific Antigen Doubling Time and Velocity at Emergence of Androgen Independence in Patients Treated with Chemotherapy. Urology 2007, 70: 527-531. PMID: 17905110, DOI: 10.1016/j.urology.2007.04.035.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAndrogen AntagonistsAndrogensAntineoplastic Agents, HormonalAntineoplastic Agents, PhytogenicDocetaxelDrug Resistance, NeoplasmHumansMaleMiddle AgedNeoplasms, Hormone-DependentPaclitaxelPrognosisProportional Hazards ModelsProstate-Specific AntigenProstatic NeoplasmsRetrospective StudiesSalvage TherapySurvival AnalysisTaxoidsTime FactorsConceptsProstate-specific antigen doubling timeAndrogen-independent prostate cancerEmergence of androgen-independent prostate cancerPatients treated with chemotherapyPSA nadirPSA valuesOverall survivalPrognostic informationShort prostate-specific antigen doubling timeEmergence of androgen independenceInstitutional prostate cancer databasePredictors of decreased OSAssociated with decreased OSAndrogen deprivation therapyCox proportional hazards regression modelsProstate cancer databaseType of chemotherapyProportional hazards regression modelsHazards regression modelsDoubling timeDeprivation therapyAndrogen independenceIntermediate prognosisProstate-specificPrognostic role
2006
Prostate specific antigen doubling time (PSA-DT) and velocity (PSA-V) provide independent prognostic information in androgen independent prostate cancer (AIPC) patients receiving chemotherapy
Daskivich T, Regan M, Kantoff P, Oh W. Prostate specific antigen doubling time (PSA-DT) and velocity (PSA-V) provide independent prognostic information in androgen independent prostate cancer (AIPC) patients receiving chemotherapy. Journal Of Clinical Oncology 2006, 24: 4616-4616. DOI: 10.1200/jco.2006.24.18_suppl.4616.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerAndrogen deprivation therapyAssociated with decreased OSPSA-DTOverall survivalPSA nadirTaxane chemotherapyLow HbFailure of androgen deprivation therapyProstate specific antigen doubling timePredictors of decreased OSPSA nadir >Short PSA DTIndependent prostate cancerType of chemotherapyCox proportional hazards regressionHigh M stagePSA-VProportional hazards regressionLog-PSADeprivation therapyPSA valuesIntermediate prognosisPrognostic factorsPrognostic significance
1978
Clinical Relevance of the Histopathological Subclassification of Diffuse Histiocytic Lymphoma
Strauchen J, Young R, Devita V, Anderson T, Fantone J, Berard C. Clinical Relevance of the Histopathological Subclassification of Diffuse Histiocytic Lymphoma. New England Journal Of Medicine 1978, 299: 1382-1387. PMID: 362206, DOI: 10.1056/nejm197812212992503.Peer-Reviewed Original ResearchConceptsComplete response rateDiffuse histiocytic lymphomaHistopathological subclassificationExcellent prognosisIntermediate prognosisBetter prognosisPoor prognosisHistiocytic lymphomaMorphologic subclassificationHistopathological categoriesHeterogeneous diseaseClinical relevancePrognosisResponse rateMorphologic featuresLymphomaChemotherapyPatientsTumorsSubclassificationSurvivalDifferencesDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply